Yep Our EV is now ( Mkt cap $333m minus $308m cash on hand ...assuming no debt ) ....only $25m ? No discussion on how to enter the remaining big 3 EU markets ....no discussion on even Real World Evidence studies or plans for them .
How long have we been selling in the UK now ....with an R-IT population estimated at 425,000 patients ...and we have a total of only 1,750 patients on Vazkepa . The big high light ...we now have 3,800 patients on Vazkepa in Spain .
We're losing $ , our Enterprise value is shrinking and our best idea is a share buyback !!!!!!! F'n disaster IMHO Kiwi
I honestly thought the SP would be down 20% like it normally is after earnings. Earnings always seem to be awful. I am more concerned with the stuff you mentioned it just seems to be same old same old with the new leadership. Nothing seems to have changed much. I would love to know what they mean by "significant revenue" in Europe by year end cause a few million a quarter pretty much is nowhere close to offset the USA market decline.